NCT02471716View on ClinicalTrials.gov

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Pigmented Villonodular SynovitisTenosynovial Giant Cell Tumor
Interventions
BIOLOGICAL

FPA008

FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks

Trial Locations (12)

33076

Institut Bergonie- CRLCC de Bordeaux et du Sud-Ouest, Bordeaux

69008

Centre Léon Bérard, Lyon

77030

The University of Texas, MD Anderson Cancer Center, Houston

90048

Cedars-Sinai Medical Center, Los Angeles

90403

Sarcoma Oncology Research Center LLC, Santa Monica

94301-5821

Stanford Medicine, Stanford

02215

Dana-Farber Cancer Institute, Boston

2333 ZA

Leiden University Medical Center, Leiden

02-781

Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie, Warsaw

110-744

Seoul National University Hospital, Seoul

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

OX3 7LE

Oxford University Hospital NHS Trust, Oxford

Sponsors
All Listed Sponsors
lead

Five Prime Therapeutics, Inc.

INDUSTRY

NCT02471716 - Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor | Biotech Hunter | Biotech Hunter